Sequential CD20 CAR-T Therapy is Superior to Salvage Chemotherapy in B-cell Lymphoma Patients with CD19 CAR-T Treatment Failure
In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T treatment is ineffective or those who relapse after a brief period of effectiveness. Beyond exploring factors that may affect the efficacy of CD19 CAR-T therapy, many doctors and researchers are actively seeking effective treatments for these patients. In June this year, Dr. Xiaoyan Ke and Dr. Kai Hu's team from Beijing GoBroad Boren Hospital published an article titled “Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure” in the Frontiers in Oncology, providing new insights into treatment options for B-cell lymphoma patients who have failed CD19 CAR-T therapy.
Dr. Zefei Jiang：Toripalimab Plus Nab-Paclitaxel in Metastatic or Recurrent Triple-Negative Breast Cancer: A Randomized Phase 3 Trial
In a significant advancement in cancer research, Dr. Zefei Jiang and his team from The Fifth Medical Center of Chinese PLA General Hospital published the article "Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial" in Nature Medicine(IF=83) on January 1, 2024. This pivotal study investigates the efficacy and safety of combining toripalimab, an immune checkpoint inhibitor, with nab-paclitaxel in treating metastatic or recurrent triple-negative breast cancer (TNBC). TNBC, marked by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, presents limited treatment options and a poor prognosis. The study addresses the urgent need for more effective therapies for this aggressive breast cancer subtype.
New Insights: IP + IV Paclitaxel Plus S-1 Boosts Survival in Gastric Cancer Patients with Peritoneal Metastasis
Editor's note: Gastric cancer remains a leading cause of cancer-related mortality, particularly in patients with peritoneal metastases, for whom treatment options are limited. The DRAGON-01 trial, a multicenter, randomized phase…
Dr. Yongmei Yin：Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial
In a significant advancement in cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases: A Randomized Double-Blind Phase 3 Equivalence Trial" in JAMA Oncology on April, 2024. This pivotal study investigates the efficacy and safety of MW032, a proposed denosumab biosimilar, in treating solid tumor-related bone metastases. Bone metastases, a common and severe complication in cancer patients, lead to skeletal-related events (SREs) that significantly impact morbidity and mortality. The study addresses the urgent need for more effective and accessible treatments for patients suffering from these severe complications.
Dr. Zefei Jiang Reviews 2023 Advances in Breast Cancer Research
In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article summarizes Professor Jiang's speeches and highlights key advances in breast cancer treatment in 2023.
ASCO GI | Advancing Targeted Therapy for Gastric Cancer: Insights from Dr. Anna Dorothea Wagner
Editor's Note: In this exclusive interview, we speak with Dr. Anna Dorothea Wagner, a leading expert in gastrointestinal oncology, about the evolving landscape of virtual targeted diagnosis and treatment for…
Dr. Zefei Jiang ‘s Overview of Breast Cancer Research Progress in 2023
In 2023, significant progress has been made in the field of breast cancer research. Dr. Zefei Jiang from The Fifth Medical Center of Chinese PLA General Hospital shared his insights and research findings at several important conferences. This article delves into Professor Jiang's speeches, exploring the key advancements in breast cancer treatment in 2023.
Unlocking New Potential: Insights from the LAPIS Phase 3 Trial on Pamrevlumab in Locally Advanced Pancreatic Cancer
Editor's note: The LAPIS Phase 3 trial was a large-scale, global, double-blind, placebo-controlled study designed to assess the efficacy of pamrevlumab in combination with chemotherapy for patients with locally advanced…
The 8th Yunling Breast Cancer Summit Forum | Dr. Qianjun Chen: Focusing on Controversies in HER2-Positive Breast Cancer, Multidisciplinary Collaboration Holds Great Promise
On July 14, to mark the 40th anniversary of Yunnan Cancer Hospital, the "8th Yunling Breast Cancer Summit Forum," hosted by the Yunnan Anti-Cancer Association and the Chinese Medical Education Association, was held in Kunming. The event gathered cutting-edge advances in breast cancer from domestic and international experts. Dr. Qianjun Chen from Guangdong Provincial Hospital of Traditional Chinese Medicine delivered a keynote report on "Consensus and Controversies in Anti-HER2 Therapy for HER2-Positive Breast Cancer." "Oncology Frontier" interviewed Professor Chen on site to share insights on the consensus and controversies in anti-HER2 therapy for HER2-positive breast cancer, guiding multidisciplinary collaboration to optimize patient management strategies, extend patient survival, and improve quality of life.